Premium
Mineralys Therapeutics Inc (MLYS)
NASDAQ
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase in... Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.27 | 2.78637770898 | 9.69 | 10.235 | 8.241 | 439390 | 9.22947801 | CS |
| 4 | -0.41 | -3.95371263259 | 10.37 | 11.09 | 8.241 | 347952 | 9.68296504 | CS |
| 12 | -2.27 | -18.5609157809 | 12.23 | 13.86 | 8.241 | 269452 | 10.52918854 | CS |
| 26 | -2.36 | -19.1558441558 | 12.32 | 15.25 | 8.241 | 209238 | 11.66360915 | CS |
| 52 | -5.87 | -37.0814908402 | 15.83 | 15.95 | 8.241 | 191958 | 12.09654437 | CS |
| 156 | -11.14 | -52.7962085308 | 21.1 | 21.98 | 5.85 | 192789 | 12.59918137 | CS |
| 260 | -11.14 | -52.7962085308 | 21.1 | 21.98 | 5.85 | 192789 | 12.59918137 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
